Ovid Therapeutics Inc.
HealthcareNASDAQ:OVID · NASDAQ Global Select
+$0.09 today
Vol 2.06M · Avg 3.04M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-13.3%
avg -57.5%
ROIC
-29.5%
avg -57.7%
ROA
-11.5%
avg -42.9%
Analysis
ROA is currently the strongest return metric at -11.5% versus its period average of -42.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jeremy Max Levin Ba Zoology Dphil Mb Bchir | Co-Founder & Executive Chairman | $1.19M | — | 73 | $3.74M | 2.83% |
Margaret Alexander | CEO, President & Director | $879,000.00 | — | 45 | $1.44M | 1.09% |
Jeffrey A. Rona | Chief Business & Financial Officer and Corporate Secretary | $825,892.00 | — | 58 | $408,750.00 | 0.31% |
Petra Kaufmann | Chief Medical Officer | — | — | 60 | — | — |
Manal Morsy | Chief Regulatory Officer | — | — | — | — | — |
Julia Tsai | Senior Vice President of Clinical Development | — | — | 51 | — | — |
Toshiya Nishi | Head of Epilepsy Research | — | — | — | — | — |
Zhong Zhong | Chief Scientific Officer | — | — | — | — | — |
Garret Bonney | Investor Relations Officer | — | — | — | — | — |
Charles Ross Carter | Senior Vice President of Finance & Financial Planning | — | — | 58 | — | — |
Victoria Fort | Senior Vice President of Corporate Affairs & Corporate Strategy | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$115,966.20
Sells
2
$29,285.65
Net Sentiment
+$86,680.55
Net buying
Most Active
LEVIN JEREMY M
3 transactions
Analysis
Insiders reported 3 buys worth $115,966.20 and 2 sells worth $29,285.65 over the last 12 months. That adds up to net buying of $86,680.55. LEVIN JEREMY M was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
MacroGenics, Inc.
NASDAQ:MGNX
$251.71M
Shattuck Labs, Inc.
NASDAQ:STTK
$236.64M
Whitehawk Therapeutics Inc
NASDAQ:WHWK
$205.72M
Oramed Pharmaceuticals Inc.
NASDAQ:ORMP
$158.38M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$133.48M
Context Therapeutics Inc.
NASDAQ:CNTX
$127.71M
InflaRx N.V.
NASDAQ:IFRX
$115.57M
Kalaris Therapeutics Inc
NASDAQ:KLRS
$80.98M
ImageneBio Inc
NASDAQ:IMA
$63.39M
Clene Inc.
NASDAQ:CLNN
$60.20M
Who manages OVID?
Ovid Therapeutics Inc. (OVID) lists 11 active executives. The top listed executive is Petra Kaufmann, Chief Medical Officer.
Are OVID insiders buying or selling?
Recent insider activity shows net buying of $50.31M.
Explore More
Continue the stock analysis
Jump to another research area for this company.